Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300352 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL13273157 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL15757659 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL1524542 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL810916 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL24080350 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL6055455 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL1524543 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL15757660 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 | |
| SCHEMBL6569696 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAEPHX2TSHRCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3281931-A1 | METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS | Elevance Renewable Sciences, Inc. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20150307438-A1 | Methods of Making Organic Compounds by Metathesis | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-9120742-B2 | Methods of making organic compounds by metathesis | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8569560-B2 | Synthesis of terminal alkenes from internal alkenes via olefin metathesis | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8501973-B2 | Synthesis of terminal alkenes from internal alkenes via olefin metathesis | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130035532-A1 | SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS | Elevance Renewable Sciences. Inc (US) | 2013-02-07 | — | — | US | disclosed |
| US-20100145086-A1 | Synthesis of Terminal Alkenes From Internal Alkenes Via Olefin Metathesis | ELEVANCE RENEWABLE SCIENCES, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2121546-A2 | METHODS OF MAKING ALPHA, OMEGA-DICARBOXYLIC ACID ALKENE DERIVATIVES BY METATHESIS | Elevance Renewable Sciences, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090264672-A1 | METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| EP-2076484-A2 | SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS | Elevance Renewable Sciences, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008140468-A2 | METHODS OF MAKING α, ω -DICARBOXYLIC ACID ALKENE DERIVATIVES BY METATHESIS | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008046106-A2 | SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264672-A1 | METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS | COASY, FASN, HAO2 | ALDH1A1 97/4885LMNA 1404/4885EPHX2 148/4885 |
| US-20150307438-A1 | Methods of Making Organic Compounds by Metathesis | COASY, FASN, HAO2 | ALDH1A1 97/4885LMNA 1404/4885EPHX2 148/4885 |
| US-20130035532-A1 | SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS | COASY, SQLE, POR | ALDH1A1 439/4885LMNA 4298/4885EPHX2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.